Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Spero Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Spero Therapeutics' CEO'su Sath Shukla, Aug2023 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 2.02M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.9% maaş ve 74.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.069% ine doğrudan sahiptir ve bu hisseler $ 50.00K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.9 yıl ve 10.4 yıldır.

Anahtar bilgiler

Sath Shukla

İcra Kurulu Başkanı

US$2.0m

Toplam tazminat

CEO maaş yüzdesi	25.9%
CEO görev süresi	1.2yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	10.4yrs

Son yönetim güncellemeleri

Recent updates

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 11

CEO Tazminat Analizi

Sath Shukla'un ücretlendirmesi Spero Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$17m
Mar 31 2024	n/a	n/a	US$23m
Dec 31 2023	US$2m	US$524k	US$23m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$2m	US$478k	-US$46m
Sep 30 2022	n/a	n/a	-US$102m
Jun 30 2022	n/a	n/a	-US$113m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$2m	US$441k	-US$90m

Tazminat ve Piyasa: Sath 'nin toplam tazminatı ($USD 2.02M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Sath 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sath Shukla (51 yo)

1.2yrs

Görev süresi

US$2,024,647

Tazminat

Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ankit Mahadevia	Co-Founder & Chairman of the Board	11.1yrs	US$2.39m	0.43% $ 312.9k
Satyavrat Shukla	President	1.2yrs	US$2.02m	0.069% $ 50.0k
Timothy Keutzer	Chief Operating Officer	1.7yrs	US$1.44m	0.13% $ 90.6k
Esther Rajavelu	CFO, Chief Business Officer & Treasurer	1.2yrs	Veri yok	Veri yok
James Brady	Chief Human Resource Officer	2.9yrs	Veri yok	Veri yok
Kamal Hamed	Chief Medical Officer	2.1yrs	Veri yok	0.22% $ 162.7k

1.9yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: SPRO 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ankit Mahadevia	Co-Founder & Chairman of the Board	11.1yrs	US$2.39m	0.43% $ 312.9k
Satyavrat Shukla	President	1.2yrs	US$2.02m	0.069% $ 50.0k
Frank Thomas	Independent Director	7.3yrs	US$88.83k	0.028% $ 20.1k
Milind Deshpande	Independent Director	10.8yrs	US$105.70k	0.058% $ 42.2k
Eric Gordon	Scientific Advisors	10.4yrs	Veri yok	Veri yok
George Drusano	Clinical Advisor	10.4yrs	Veri yok	Veri yok
Steven Gilman	Scientific Advisor	no data	Veri yok	Veri yok
Patrick V. J. Vink	Lead Independent Director	9.1yrs	US$93.19k	0.028% $ 20.1k
Gordon Archer	Clinical Advisor	10.4yrs	Veri yok	Veri yok
David Livermore	Scientific Advisor	no data	Veri yok	Veri yok
Paul Ambrose	Clinical Advisor	10.4yrs	Veri yok	Veri yok
Cynthia Smith	Independent Director	5.6yrs	US$73.20k	0.028% $ 20.1k

10.4yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SPRO 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.4 yıldır).

Spero Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

President notifies of intention to sell stock

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Recent updates

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 46%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Consensus EPS estimates upgraded to US$1.09 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 50%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Investor sentiment improves as stock rises 15%

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates fall by 24%

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

President notifies of intention to sell stock

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 21%, EPS downgraded

Price target increased by 18% to US$7.50

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Consensus estimates of losses per share improve by 10%

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Consensus estimates of losses per share improve by 38%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 35%

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Consensus revenue estimates fall by 36%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 53%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Consensus revenue estimates increase by 183%

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics appoints Kamal Hamed MD CMO

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Consensus revenue estimates increase by 69%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind